- Metsera, Inc. announced **positive topline data** from its Phase 2b VESPER-1 and positive interim data from VESPER-3 trials for **MET-097i**, an ultra-long acting GLP-1 receptor agonist.  **[2040807_0001193125-25-223440_d943312dex991.htm:0]** **[2040807_0001193125-25-223440_d943312d8k.htm:1]** **[2040807_0001193125-25-223440_d943312d8k.htm:2]** 
- In the VESPER-1 trial, MET-097i demonstrated a mean placebo-subtracted **weight loss of up to 14.1% after 28 weeks**.  **[2040807_0001193125-25-223440_d943312dex991.htm:0]** **[2040807_0001193125-25-223440_d943312dex991.htm:1]** **[2040807_0001193125-25-223440_d943312d8k.htm:2]** 
- MET-097i showed potentially **class-leading tolerability** in both trials, with a minimal diarrhea signal and a risk difference from placebo of **13% for nausea and 11% for vomiting** at the highest evaluated dose in VESPER-3 after 12 weeks.  **[2040807_0001193125-25-223440_d943312dex991.htm:0]** **[2040807_0001193125-25-223440_d943312dex991.htm:1]** **[2040807_0001193125-25-223440_d943312d8k.htm:2]** 
- Based on these results, Metsera is on track to initiate a **global Phase 3 program in late 2025**.  **[2040807_0001193125-25-223440_d943312dex991.htm:0]** **[2040807_0001193125-25-223440_d943312d8k.htm:2]** **[2040807_0001193125-25-223440_d943312dex991.htm:2]**

Metsera Reports Positive Phase 2b Results for MET-097i

- Pfizer Inc. will acquire Metsera, Inc. for **$47.50 per share in cash** at closing, representing an initial enterprise value of approximately **$4.9 billion**.  **[2040807_0001193125-25-210030_d921605dex991.htm:1]** **[2040807_0001193125-25-210030_d921605d8k.htm:2]** 
- The agreement includes a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to **$22.50 per share** in cash, tied to three specific clinical and regulatory milestones.  **[2040807_0001193125-25-210030_d921605dex991.htm:1]** **[2040807_0001193125-25-210030_d921605d8k.htm:2]** 
- The transaction, unanimously approved by the Boards of Directors of both companies, is expected to close in the **fourth quarter of 2025**.  **[2040807_0001193125-25-210030_d921605dex991.htm:1]** **[2040807_0001193125-25-210030_d921605d8k.htm:2]** 
- This acquisition will add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline, focusing on obesity and cardiometabolic diseases.  **[2040807_0001193125-25-210030_d921605dex991.htm:1]**

Metsera (MTSR)